{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T08:03:46Z","timestamp":1771661026077,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Public Health"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The first large serosurvey in Iran found a SARS-CoV-2 antibody seroprevalence of 17.1% among the general population in the first wave of the epidemic by April, 2020. The purpose of the current study was to assess the seroprevalence of COVID-19 infection among Iranian general population after the third wave of the disease.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This population-based cross-sectional study was conducted on 7411 individuals aged \u226510\u2009years old in 16 cities across 15 provinces in Iran between January and March, 2021. We randomly sampled individuals registered in the Iranian electronic health record system based on their national identification numbers and invited them by telephone to a healthcare center for data collection. Presence of SARS-CoV-2-specific IgG and IgM antibodies was assessed using the SARS-CoV-2 ELISA kits. The participants were also asked about their recent COVID-19-related symptoms, including cough, fever, chills, sore throat, headache, dyspnea, diarrhea, anosmia, conjunctivitis, weakness, myalgia, arthralgia, altered level of consciousness, and chest pain. The seroprevalence was estimated after adjustment for population weighting and test performance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The overall population-weighted seroprevalence adjusted for test performance was 34.2% (95% CI 31.0-37.3), with an estimated 7,667,874 (95% CI 6,950,412-8,362,915) infected individuals from the 16 cities. The seroprevalence varied between the cities, from the highest estimate in Tabriz (39.2% [95% CI 33.0-45.5]) to the lowest estimate in Kerman (16.0% [95% CI 10.7-21.4]). In the 16 cities studied, 50.9% of the seropositive individuals did not report a history of symptoms suggestive of COVID-19, implying an estimation of 3,902,948 (95% CI 3,537,760-4,256,724) asymptomatic infected individuals.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Nearly one in three individuals were exposed to SARS-CoV-2 in the studied cities by March 2021. The seroprevalence increased about two-fold between April, 2020, and March, 2021.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12889-022-13464-7","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T08:02:48Z","timestamp":1653292968000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Seroprevalence of SARS-CoV-2 antibody among urban Iranian population: findings from the second large population-based cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Mohammad","family":"Zamani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hossein","family":"Poustchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sahar","family":"Dalvand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Sharafkhah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seyed Abbas","family":"Motevalian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saeid","family":"Eslami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amir","family":"Emami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammad Hossein","family":"Somi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamshid","family":"Yazdani-Charati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nader","family":"Saki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manoochehr","family":"Karami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farid","family":"Najafi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iraj","family":"Mohebbi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasrollah","family":"Veisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Hormati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farhad","family":"Pourfarzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Ghadimi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Ansari-Moghaddam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamid","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gholamreza","family":"Roshandel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fariborz","family":"Mansour-Ghanaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Farahnaz","family":"Joukar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amaneh","family":"Shayanrad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sareh","family":"Eghtesad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmadreza","family":"Niavarani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Delavari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soudeh","family":"Kaveh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akbar","family":"Feizesani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melineh","family":"Markarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Shafighian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alireza","family":"Sadjadi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Darvishian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reza","family":"Malekzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"13464_CR1","volume-title":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)","author":"Johns Hopkins University of Medicine Coronavirus Resource Center","year":"2021","unstructured":"Johns Hopkins University of Medicine Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2021; Available online at: https:\/\/coronavirus.jhu.edu\/map.html (Accessed 8 May 2022)."},{"key":"13464_CR2","doi-asserted-by":"publisher","first-page":"e598","DOI":"10.1016\/1012FS2214-1109X(1021)00026-00027","volume":"9","author":"X Chen","year":"2021","unstructured":"Chen X, Chen Z, Azman AS, Deng X, Sun R, Zhao Z, et al. Serological evidence of human infection with SARS-CoV-2: a systematic review and meta-analysis. Lancet Glob Health. 2021;9:e598\u2013609. https:\/\/doi.org\/10.1016\/1012FS2214-1109X(1021)00026-00027.","journal-title":"Lancet Glob Health"},{"key":"13464_CR3","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/1012FS1473-3099(1020)30858-30856","volume":"21","author":"H Poustchi","year":"2021","unstructured":"Poustchi H, Darvishian M, Mohammadi Z, Shayanrad A, Delavari A, Bahadorimonfared A, et al. SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study. Lancet Infect Dis. 2021;21:473\u201381. https:\/\/doi.org\/10.1016\/1012FS1473-3099(1020)30858-30856.","journal-title":"Lancet Infect Dis"},{"key":"13464_CR4","first-page":"13","volume":"94","author":"M Saki","year":"2021","unstructured":"Saki M, Ghanbari MK, Behzadifar M, Imani-Nasab MH, Azari S, Bakhtiari A, et al. The impact of the social distancing policy on COVID-19 incidence cases and deaths in Iran from February 2020 to January 2021: insights from an interrupted time series analysis. Yale J Biol Med. 2021;94:13\u201321.","journal-title":"Yale J Biol Med"},{"key":"13464_CR5","volume-title":"Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection, May 26, 2020. Version 2.0","author":"World Health Organization","year":"2020","unstructured":"World Health Organization. Population-based age-stratified seroepidemiological investigation protocol for coronavirus 2019 (COVID-19) infection, May 26, 2020. Version 2.0. Geneva: WHO; 2020."},{"key":"13464_CR6","first-page":"592","volume":"22","author":"L Doshmangir","year":"2019","unstructured":"Doshmangir L, Bazyar M, Majdzadeh R, Takian A. So near, so far: four decades of health policy reforms in Iran, achievements and challenges. Arch Iran Med. 2019;22:592\u2013605.","journal-title":"Arch Iran Med"},{"key":"13464_CR7","doi-asserted-by":"publisher","first-page":"216","DOI":"10.34172\/aim.32020.34101","volume":"23","author":"A Raeisi","year":"2020","unstructured":"Raeisi A, Tabrizi JS, Gouya MM. IR of Iran national mobilization against COVID-19 epidemic. Arch Iran Med. 2020;23:216\u20139. https:\/\/doi.org\/10.34172\/aim.32020.34101.","journal-title":"Arch Iran Med"},{"key":"13464_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.34171\/34172Fmjiri.34134.34127","volume":"34","author":"A Ahmadi","year":"2020","unstructured":"Ahmadi A, Fadaei Y, Shirani M, Rahmani F. Modeling and forecasting trend of COVID-19 epidemic in Iran until may 13, 2020. Med J Islam Repub Iran. 2020;34:27. https:\/\/doi.org\/10.34171\/34172Fmjiri.34134.34127.","journal-title":"Med J Islam Repub Iran"},{"key":"13464_CR9","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1016\/j.cmi.2021.1606.1002","volume":"27","author":"K Khalagi","year":"2021","unstructured":"Khalagi K, Gharibzadeh S, Khalili D, Mansournia MA, Samiee SM, Aghamohamadi S, et al. Prevalence of COVID-19 in Iran: results of the first survey of the Iranian COVID-19 serological surveillance program. Clin Microbiol Infect. 2021;27:1666\u201371. https:\/\/doi.org\/10.1016\/j.cmi.2021.1606.1002.","journal-title":"Clin Microbiol Infect"},{"key":"13464_CR10","unstructured":"Pishtaz Teb. Diagnostics SARS-CoV-2 IgG and IgM ELISA kits. Available online at: http:\/\/pishtazteb.com\/en\/sars-cov-2-igg-elisa-kit\/, https:\/\/pishtazteb.com\/en\/sars-cov-2-igm-elisa-kit\/."},{"key":"13464_CR11","volume-title":"COVID-19 signs, symptoms and severity of disease: A clinician guide","author":"Canada.ca","year":"2021","unstructured":"Canada.ca. COVID-19 signs, symptoms and severity of disease: A clinician guide. 2021; Available online at: https:\/\/www.canada.ca\/en\/public-health\/services\/diseases\/2019-novel-coronavirus-infection\/guidance-documents\/signs-symptoms-severity.html#a1 (Accessed 17 June 2021)."},{"key":"13464_CR12","doi-asserted-by":"publisher","first-page":"1724","DOI":"10.1002\/jmv.25800","volume":"92","author":"I Cassaniti","year":"2020","unstructured":"Cassaniti I, Novazzi F, Giardina F, Salinaro F, Sachs M, Perlini S, et al. Performance of VivaDiag COVID-19 IgM\/IgG rapid test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J Med Virol. 2020;92:1724\u20137. https:\/\/doi.org\/10.1002\/jmv.25800.","journal-title":"J Med Virol"},{"key":"13464_CR13","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1016\/j.cmi.2020.1005.1023","volume":"26","author":"J Van Elslande","year":"2020","unstructured":"Van Elslande J, Houben E, Depypere M, Brackenier A, Desmet S, Andr\u00e9 E, et al. Diagnostic performance of seven rapid IgG\/IgM antibody tests and the Euroimmun IgA\/IgG ELISA in COVID-19 patients. Clin Microbiol Infect. 2020;26:1082\u20137. https:\/\/doi.org\/10.1016\/j.cmi.2020.1005.1023.","journal-title":"Clin Microbiol Infect"},{"key":"13464_CR14","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1093\/ije\/dyab1010","volume":"50","author":"E Bendavid","year":"2021","unstructured":"Bendavid E, Mulaney B, Sood N, Shah S, Bromley-Dulfano R, Lai C, et al. Covid-19 antibody seroprevalence in Santa Clara county, California. Int J Epidemiol. 2021;50:410\u20139. https:\/\/doi.org\/10.1093\/ije\/dyab1010.","journal-title":"Int J Epidemiol"},{"key":"13464_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/aos\/1176344552","volume":"7","author":"B Efron","year":"1979","unstructured":"Efron B. Bootstrap methods: another look at the jackknife. Ann Stat. 1979;7:1\u201326.","journal-title":"Ann Stat"},{"key":"13464_CR16","volume-title":"COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU)","author":"Johns Hopkins University of Medicine Coronavirus Resource Center","year":"2021","unstructured":"Johns Hopkins University of Medicine Coronavirus Resource Center. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU). 2021; Available online at: https:\/\/coronavirus.jhu.edu\/map.html (Accessed 31 Mar 2021)."},{"key":"13464_CR17","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1001\/jamainternmed.2020.4130","volume":"180","author":"FP Havers","year":"2020","unstructured":"Havers FP, Reed C, Lim T, Montgomery JM, Klena JD, Hall AJ, et al. Seroprevalence of antibodies to SARS-CoV-2 in 10 sites in the United States, March 23-May 12, 2020. JAMA Intern Med. 2020;180:1576\u201386. https:\/\/doi.org\/10.1001\/jamainternmed.2020.4130.","journal-title":"JAMA Intern Med"},{"key":"13464_CR18","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.1016\/s2589-7500(1020)30293-30294","volume":"3","author":"B Rader","year":"2021","unstructured":"Rader B, White LF, Burns MR, Chen J, Brilliant J, Cohen J, et al. Mask-wearing and control of SARS-CoV-2 transmission in the USA: a cross-sectional study. Lancet Digit Health. 2021;3:e148\u201357. https:\/\/doi.org\/10.1016\/s2589-7500(1020)30293-30294.","journal-title":"Lancet Digit Health"},{"key":"13464_CR19","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/s1473-3099(1021)00475-00478","volume":"22","author":"KA Twohig","year":"2022","unstructured":"Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B. 1.617. 2) compared with alpha (B. 1.1. 7) variants of concern: a cohort study. Lancet Infect Dis. 2022;22:35\u201342. https:\/\/doi.org\/10.1016\/s1473-3099(1021)00475-00478.","journal-title":"Lancet Infect Dis"},{"key":"13464_CR20","volume-title":"COVID-19 results Briefing: eastern Mediterranean region, 2021","author":"Institute of Health Metrics and Evaluation (IHME)","year":"2021","unstructured":"Institute of Health Metrics and Evaluation (IHME). COVID-19 results Briefing: eastern Mediterranean region, 2021. 2021; Available online at: http:\/\/www.healthdata.org\/sites\/default\/files\/files\/Projects\/COVID\/2021\/44567_briefing_Eastern_Mediterranean_Region_4.pdf (Accessed 6 Mar 2021)."},{"key":"13464_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s12889-12021-10183-12883","volume":"21","author":"F Pourmalek","year":"2021","unstructured":"Pourmalek F, Hemami MR, Janani L, Moradi-Lakeh M. Rapid review of COVID-19 epidemic estimation studies for Iran. BMC Public Health. 2021;21:257. https:\/\/doi.org\/10.1186\/s12889-12021-10183-12883.","journal-title":"BMC Public Health"},{"key":"13464_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ijid.2021.1005.1040","volume":"108","author":"MV Murhekar","year":"2021","unstructured":"Murhekar MV, Bhatnagar T, Thangaraj JWV, Saravanakumar V, Kumar MS, Selvaraju S, et al. SARS-CoV-2 seroprevalence among the general population and healthcare workers in India, December 2020\u2013January 2021. Int J Infect Dis. 2021;108:145\u201355. https:\/\/doi.org\/10.1016\/j.ijid.2021.1005.1040.","journal-title":"Int J Infect Dis"},{"key":"13464_CR23","doi-asserted-by":"publisher","first-page":"e925","DOI":"10.1016\/s2214-1109x(1021)00173-x","volume":"9","author":"C \u00c1lvarez-Antonio","year":"2021","unstructured":"\u00c1lvarez-Antonio C, Meza-S\u00e1nchez G, Calampa C, Casanova W, Carey C, Alava F, et al. Seroprevalence of anti-SARS-CoV-2 antibodies in Iquitos, Peru in July and august, 2020: a population-based study. Lancet Glob Health. 2021;9:e925\u201331. https:\/\/doi.org\/10.1016\/s2214-1109x(1021)00173-x.","journal-title":"Lancet Glob Health"},{"key":"13464_CR24","doi-asserted-by":"publisher","first-page":"e1390","DOI":"10.1016\/s2214-1109x(1320)30387-30389","volume":"8","author":"PC Hallal","year":"2020","unstructured":"Hallal PC, Hartwig FP, Horta BL, Silveira MF, Struchiner CJ, Vidaletti LP, et al. SARS-CoV-2 antibody prevalence in Brazil: results from two successive nationwide serological household surveys. Lancet Glob Health. 2020;8:e1390\u20138. https:\/\/doi.org\/10.1016\/s2214-1109x(1320)30387-30389.","journal-title":"Lancet Glob Health"},{"key":"13464_CR25","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/s2214-1109x(1020)30544-30541","volume":"9","author":"MV Murhekar","year":"2021","unstructured":"Murhekar MV, Bhatnagar T, Selvaraju S, Saravanakumar V, Thangaraj JWV, Shah N, et al. SARS-CoV-2 antibody seroprevalence in India, august\u2013September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021;9:e257\u201366. https:\/\/doi.org\/10.1016\/s2214-1109x(1020)30544-30541.","journal-title":"Lancet Glob Health"},{"key":"13464_CR26","doi-asserted-by":"publisher","first-page":"101205","DOI":"10.1016\/j.arr.102020.101205","volume":"65","author":"Y Chen","year":"2021","unstructured":"Chen Y, Klein SL, Garibaldi BT, Li H, Wu C, Osevala NM, et al. Aging in COVID-19: vulnerability, immunity and intervention. Ageing Res Rev. 2021;65:101205. https:\/\/doi.org\/10.1016\/j.arr.102020.101205.","journal-title":"Ageing Res Rev"},{"key":"13464_CR27","doi-asserted-by":"publisher","first-page":"6506","DOI":"10.1002\/jmv.27152","volume":"93","author":"F Zeng","year":"2021","unstructured":"Zeng F, Wu M, Wang J, Li J, Hu G, Wang L. Over 1-year duration and age difference of SARS-CoV-2 antibodies in convalescent COVID-19 patients. J Med Virol. 2021;93:6506\u201311. https:\/\/doi.org\/10.1002\/jmv.27152.","journal-title":"J Med Virol"},{"key":"13464_CR28","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/1012Fj.cmi.2020.1010.1020","volume":"27","author":"A Rostami","year":"2021","unstructured":"Rostami A, Sepidarkish M, Leeflang MMG, Riahi SM, Nourollahpour Shiadeh M, Esfandyari S, et al. SARS-CoV-2 seroprevalence worldwide: a systematic review and meta-analysis. Clin Microbiol Infect. 2021;27:331\u201340. https:\/\/doi.org\/10.1016\/1012Fj.cmi.2020.1010.1020.","journal-title":"Clin Microbiol Infect"},{"key":"13464_CR29","doi-asserted-by":"publisher","first-page":"9081491","DOI":"10.1155\/9082021\/9081491","volume":"2021","author":"HA Balou","year":"2021","unstructured":"Balou HA, Yaghubi Kalurazi T, Joukar F, Hassanipour S, Shenagari M, Khoshsorour M, et al. High Seroprevalence of SARS-CoV-2 (COVID-19)-specific antibodies among healthcare workers: a cross-sectional study in Guilan. Iran J Environ Public Health. 2021;2021:9081491. https:\/\/doi.org\/10.1155\/9082021\/9081491.","journal-title":"Iran J Environ Public Health"},{"key":"13464_CR30","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1017\/1012Fice.2020.1086","volume":"41","author":"M Abdi","year":"2020","unstructured":"Abdi M. Coronavirus disease 2019 (COVID-19) outbreak in Iran: actions and problems. Infect Control Hosp Epidemiol. 2020;41:754\u20135. https:\/\/doi.org\/10.1017\/1012Fice.2020.1086.","journal-title":"Infect Control Hosp Epidemiol"},{"key":"13464_CR31","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/1012FS1473-3099(1021)00058-X","volume":"21","author":"M Darvishian","year":"2021","unstructured":"Darvishian M, Sharafkhah M, Poustchi H, Malekzadeh R. Estimates of anti-SARS-CoV-2 antibody seroprevalence in Iran \u2013 Authors\u2019 reply. Lancet Infect Dis. 2021;21:604\u20135. https:\/\/doi.org\/10.1016\/1012FS1473-3099(1021)00058-X.","journal-title":"Lancet Infect Dis"},{"key":"13464_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1093\/infdis\/jiab1522","volume":"225","author":"AT Chamberlain","year":"2022","unstructured":"Chamberlain AT, Toomey KE, Bradley H, Hall EW, Fahimi M, Lopman BA, et al. Cumulative incidence of SARS-CoV-2 infections among adults in Georgia, USA, august-December 2020. J Infect Dis. 2022;225:396\u2013403. https:\/\/doi.org\/10.1093\/infdis\/jiab1522.","journal-title":"J Infect Dis"},{"key":"13464_CR33","doi-asserted-by":"publisher","first-page":"e0254667","DOI":"10.1371\/journal.pone.0254667","volume":"16","author":"G Davis","year":"2021","unstructured":"Davis G, York AJ, Bacon WC, Lin S-C, McNeal MM, Yarawsky AE, et al. Seroprevalence of SARS-CoV-2 infection in Cincinnati Ohio USA from august to December 2020. PLoS One. 2021;16:e0254667. https:\/\/doi.org\/10.1371\/journal.pone.0254667.","journal-title":"PLoS One"},{"key":"13464_CR34","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s10654-10021-00796-10658","volume":"36","author":"L Espenhain","year":"2021","unstructured":"Espenhain L, Tribler S, Sv\u00e6rke J\u00f8rgensen C, Holm Hansen C, Wolff S\u00f6nksen U, Ethelberg S. Prevalence of SARS-CoV-2 antibodies in Denmark: nationwide, population-based seroepidemiological study. Eur J Epidemiol. 2021;36:715\u201325. https:\/\/doi.org\/10.1007\/s10654-10021-00796-10658.","journal-title":"Eur J Epidemiol"},{"key":"13464_CR35","doi-asserted-by":"publisher","first-page":"e007271","DOI":"10.1136\/bmjgh-002021-007271","volume":"6","author":"MB Barrie","year":"2021","unstructured":"Barrie MB, Lakoh S, Kelly JD, Kanu JS, Squire JS, Koroma Z, et al. SARS-CoV-2 antibody prevalence in Sierra Leone, march 2021: a cross-sectional, nationally representative, age-stratified serosurvey. BMJ Glob Health. 2021;6:e007271. https:\/\/doi.org\/10.1136\/bmjgh-002021-007271.","journal-title":"BMJ Glob Health"},{"key":"13464_CR36","doi-asserted-by":"publisher","first-page":"3020","DOI":"10.3201\/eid2712.211465","volume":"27","author":"J Kleynhans","year":"2021","unstructured":"Kleynhans J, Tempia S, Wolter N, von Gottberg A, Bhiman JN, Buys A, et al. SARS-CoV-2 Seroprevalence in a rural and urban household cohort during first and second waves of infections, South Africa, July 2020-march 2021. Emerg Infect Dis. 2021;27:3020\u20139. https:\/\/doi.org\/10.3201\/eid2712.211465.","journal-title":"Emerg Infect Dis"},{"key":"13464_CR37","volume-title":"Coronavirus Disease (COVID-19) Dashboard","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Coronavirus Disease (COVID-19) Dashboard. 2021; Available online at: https:\/\/covid19.who.int\/region\/emro\/country\/ir (Accessed 6 May 2022)."},{"key":"13464_CR38","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1186\/s12889-12020-09704-12883","volume":"20","author":"F Tohidinezhad","year":"2020","unstructured":"Tohidinezhad F, Khorsand A, Zakavi SR, Rezvani R, Zarei-Ghanavati S, Abrishami M, et al. The burden and predisposing factors of non-communicable diseases in Mashhad University of Medical Sciences personnel: a prospective 15-year organizational cohort study protocol and baseline assessment. BMC Public Health. 2020;20:1637. https:\/\/doi.org\/10.1186\/s12889-12020-09704-12883.","journal-title":"BMC Public Health"},{"key":"13464_CR39","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/s0140-6736(1020)31483-31485","volume":"396","author":"M Poll\u00e1n","year":"2020","unstructured":"Poll\u00e1n M, P\u00e9rez-G\u00f3mez B, Pastor-Barriuso R, Oteo J, Hern\u00e1n MA, P\u00e9rez-Olmeda M, et al. Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study. Lancet. 2020;396:535\u201344. https:\/\/doi.org\/10.1016\/s0140-6736(1020)31483-31485.","journal-title":"Lancet."}],"container-title":["BMC Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-13464-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12889-022-13464-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12889-022-13464-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T08:03:02Z","timestamp":1653292982000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpublichealth.biomedcentral.com\/articles\/10.1186\/s12889-022-13464-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["13464"],"URL":"https:\/\/doi.org\/10.1186\/s12889-022-13464-7","relation":{},"ISSN":["1471-2458"],"issn-type":[{"value":"1471-2458","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"9 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The written informed consent was taken from all participants after a full explanation of the study. We obtained the children\u2019 consent from their parents or legal guardians. The study protocol was approved by the ethics committee of Tehran University of Medical Sciences (IR.TUMS.VCR.REC.1399.308). All methods were carried out in accordance with relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"We declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1031"}}